Clark Estates Inc Shattuck Labs, Inc. Transaction History

Clark Estates Inc

$390 Million
Q2 2024

A detailed history of Clark Estates Inc transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Clark Estates Inc holds 1,475,648 shares of STTK stock, worth $2.83 Million. This represents 1.46% of its overall portfolio holdings.

Number of Shares

1,475,648

Previous 1,475,648 -0.0%

Holding current value

$2.83 Million

Previous $13.2 Million 56.82%

% of portfolio

1.46%

Previous 3.07%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$2.5 - $4.72 $11,875 - $22,420	-4,750 Reduced 0.32%	1,475,648 $4.34 Million
Q4 2022 Feb 08, 2023	BUY	$1.96 - $3.26 $270,397 - $449,743	137,958 Added 10.28%	1,480,398 $3.4 Million
Q3 2022 Nov 15, 2022	BUY	$2.6 - $5.52 $3.49 Million - $7.41 Million	1,342,440 New	1,342,440 $3.63 Million
Q2 2022 Aug 08, 2022	BUY	$2.7 - $4.59 $287,550 - $488,835	106,500 Added 8.58%	1,347,640 $5.47 Million
Q1 2022 May 13, 2022	BUY	$4.22 - $8.89 $1.81 Million - $3.82 Million	429,500 Added 52.92%	1,241,140 $5.29 Million
Q4 2021 Feb 14, 2022	BUY	$8.36 - $21.08 $20,900 - $52,699	2,500 Added 0.31%	811,640 $6.91 Million
Q3 2021 Nov 12, 2021	BUY	$17.57 - $28.95 $407,624 - $671,640	23,200 Added 2.95%	809,140 $16.5 Million
Q2 2021 Aug 10, 2021	SELL	$24.14 - $37.68 $17.2 Million - $26.8 Million	-711,164 Reduced 47.5%	785,940 $22.8 Million
Q1 2021 May 14, 2021	BUY	$27.92 - $52.5 $19.5 Million - $36.6 Million	697,492 Added 87.23%	1,497,104 $43.8 Million
Q4 2020 Feb 09, 2021	BUY	$19.0 - $57.61 $15.2 Million - $46.1 Million	799,612 New	799,612 $41.9 Million

Others Institutions Holding STTK

# of Institutions

Shares Held

26.8M

Call Options Held

3.1K

Put Options Held

23.9K

View Full List

About Shattuck Labs, Inc.

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $81.4M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

More about STTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Clark Estates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Clark Estates Inc with notifications on news.

Account

Clark Estates Inc Shattuck Labs, Inc. Transaction History